Prot #HM-EMSI-202: A Single-Arm, Open-Label, Phase 2 Study Evaluating The Efficacy, Safety And Pharmacokinetics Of HM61713 In Patients With T790M-Positive Non-Small Cell Lung Cancer (NSCLC) After Treatment With An Epidermal Growth Factor Receptor-Tyrosine

Project: Research project

Project Details

StatusFinished
Effective start/end date1/26/161/26/19

Funding

  • Parexel (Prot #HM-EMSI-202)
  • Hanmi Pharmaceutical Co., Ltd. (Prot #HM-EMSI-202)